Dermatophagoides pteronyssinus allergen-specific antibodies (IgE and IgG) (HDM-specific IgE/IgG)

This target refers to the polyclonal population of Immunoglobulin E (IgE) and Immunoglobulin G (IgG) antibodies specific to allergens from the house dust mite, Dermatophagoides pteronyssinus (HDM). In sensitized individuals, HDM-specific IgE binds to high-affinity FcεRI receptors on immune effector cells such as mast cells and basophils; subsequent exposure to Der p allergens triggers receptor cross-linking and the release of inflammatory mediators like histamine (Galli et al., 2008, Nature). Conversely, IgG antibodies, particularly the IgG4 subclass induced during allergen immunotherapy (AIT), act as "blocking antibodies" by competing with IgE for allergen binding or by signaling through inhibitory FcγRIIb receptors on B cells and effector cells (Shamji & Durham, 2017, JACI). Therapeutic strategies often aim to modulate this axis by reducing the levels or activity of HDM-specific IgE or by increasing the levels of protective IgG4. Monoclonal antibodies like omalizumab directly target the Fc region of free IgE to prevent its binding to receptors, effectively lowering the sensitivity of effector cells to HDM allergens (NCBI, StatPearls). Allergen immunotherapy (AIT) uses controlled, escalating doses of Der p allergens to shift the immune response from a Th2-driven IgE production toward a more tolerant state characterized by the production of allergen-specific IgG4 and regulatory T cells (Akdis & Akdis, 2014, Nature Reviews Immunology). Monitoring the ratio of specific IgE to IgG4 is a common clinical approach to assess the efficacy of these treatments in managing allergic asthma and rhinitis (Bousquet et al., 2020, Lancet).

Other names

House dust mite specific antibodiesAnti-Der p antibodiesHDM-specific IgEHDM-specific IgGDer p 1 specific antibodiesDust mite reactive immunoglobulins

Neutralization of free IgE to prevent binding to high-affinity FcεRI receptors on effector cells and induction of allergen-specific IgG4 blocking antibodies to inhibit IgE-mediated mast cell activation and facilitate immune tolerance.